TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03005691

Intervention type: RADIATION
Intervention: Spectroscopy
Description: Spectroscopy is a noninvasive method to assess brain chemistry. The signal of the hydrogen atom attached to a certain molecule or metabolite has a particular frequency associated with a given metabolite. The utility of Spectroscopy is based on the fact thet the nuclei of atoms have magnetic properties that can be used to obtain chemical information regarding both the type of molecule and it is concentration.~The subjects will be scanned on a 3-T Siemens system and an 12-channel phased-array coil will be used to provide an optimum signal-to-noise ratio for spectroscopy data.

Intervention type: RADIATION
Intervention: Spectroscopy
Description: Spectroscopy is a noninvasive method to assess brain chemistry. The signal of the hydrogen atom attached to a certain molecule or metabolite has a particular frequency associated with a given metabolite. The utility of Spectroscopy is based on the fact thet the nuclei of atoms have magnetic properties that can be used to obtain chemical information regarding both the type of molecule and it is concentration.~The subjects will be scanned on a 3-T Siemens system and an 12-channel phased-array coil will be used to provide an optimum signal-to-noise ratio for spectroscopy data.

Intervention type: RADIATION
Intervention: Spectroscopy
Description: Spectroscopy is a noninvasive method to assess brain chemistry. The signal of the hydrogen atom attached to a certain molecule or metabolite has a particular frequency associated with a given metabolite. The utility of Spectroscopy is based on the fact thet the nuclei of atoms have magnetic properties that can be used to obtain chemical information regarding both the type of molecule and it is concentration.~The subjects will be scanned on a 3-T Siemens system and an 12-channel phased-array coil will be used to provide an optimum signal-to-noise ratio for spectroscopy data.

Intervention type: OTHER
Intervention: Questionnaires
Description: Questionnaires are important to assess the chronic pain and their impact in the quality of life. For this reason, we will assess the Brief Pain Inventory (BPI), it is used to evaluate the subject's perception of pain severity and its interference. Moreover, we will assess neuropathic pain symptoms with the NPSI to detect paresthesia/dysaesthesia, evoked pain and paroxysmal pain. The catastrophizing score will be measured with the Pain Catastrophizing Helplessness Subscale. Also,we will assess the disability after whiplash using the Neck Disability Index.
Study: NCT02554578

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multidisciplinary follow-up programme supported by mHealth
Description: The follow-up programme integrates an online health platform (app and web) to monitor patients remotely, into the multidisciplinary team workflow, in order to improve heart transplant management.~Patients will use the mobile application designed to help them to manage their health issues and facilitate communication with the transplant team.~Data recorded manually by the patient using the mHealth application include pharmacotherapeutic information (medication adherence, barriers to adherence, side effects, interactions, etc.), clinical symptoms and other relevant clinical information (blood pressure, cardiac frequency, exercise, glucose level, diet, mood, etc.).~mHealth will be used by the transplant team as a complementary way of deliver patient care. Analysis of the data collected by the multidisciplinary team may help to prioritise and provide personalized pharmacotherapeutic and medical interventions to patients and their families.
Study: NCT03972878

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: control snack
Description: dry fruit snack (200 kcal) + 250 ml water

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: control cream
Description: commercial spreadable cocoa and hazelnut cream (200 kcal)+ 250 ml water

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cream version 1
Description: commercial spreadable cocoa and hazelnut cream (200 kcal), version 1+ 250 ml water
Study: NCT03005691

Intervention type: OTHER
Intervention: Questionnaires
Description: Questionnaires are important to assess the chronic pain and their impact in the quality of life. For this reason, we will assess the Brief Pain Inventory (BPI), it is used to evaluate the subject's perception of pain severity and its interference. Moreover, we will assess neuropathic pain symptoms with the NPSI to detect paresthesia/dysaesthesia, evoked pain and paroxysmal pain. The catastrophizing score will be measured with the Pain Catastrophizing Helplessness Subscale. Also,we will assess the disability after whiplash using the Neck Disability Index.

Intervention type: OTHER
Intervention: Questionnaires
Description: Questionnaires are important to assess the chronic pain and their impact in the quality of life. For this reason, we will assess the Brief Pain Inventory (BPI), it is used to evaluate the subject's perception of pain severity and its interference. Moreover, we will assess neuropathic pain symptoms with the NPSI to detect paresthesia/dysaesthesia, evoked pain and paroxysmal pain. The catastrophizing score will be measured with the Pain Catastrophizing Helplessness Subscale. Also,we will assess the disability after whiplash using the Neck Disability Index.

Intervention type: PROCEDURE
Intervention: Conditioned Pain Modulation
Description: Conditioned Pain Modulation over the tenar eminence. The test will be a heat tonic stimulus which evoke a 3-pain intensity. The conditioning stimulus will be a cold water immersion (12ºC)

Intervention type: PROCEDURE
Intervention: Conditioned Pain Modulation
Description: Conditioned Pain Modulation over the tenar eminence. The test will be a heat tonic stimulus which evoke a 3-pain intensity. The conditioning stimulus will be a cold water immersion (12ºC)

Intervention type: PROCEDURE
Intervention: Conditioned Pain Modulation
Description: Conditioned Pain Modulation over the tenar eminence. The test will be a heat tonic stimulus which evoke a 3-pain intensity. The conditioning stimulus will be a cold water immersion (12ºC)
Study: NCT04981080

Intervention type: DIAGNOSTIC_TEST
Intervention: Urodynamic study
Description: The urodynamic assessment, including noninstrumented uroflowmetry, filling cystometry with 35°C distilled water at a rate of 60 mL/sec, a pressure flow study, and urethral pressure profilometry, was performed with the patient in a sitting position according to the recommendations by the International Continence Society.

Intervention type: DIAGNOSTIC_TEST
Intervention: Urodynamic study
Description: The urodynamic assessment, including noninstrumented uroflowmetry, filling cystometry with 35°C distilled water at a rate of 60 mL/sec, a pressure flow study, and urethral pressure profilometry, was performed with the patient in a sitting position according to the recommendations by the International Continence Society.
Study: NCT03972878

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cream version 2
Description: commercial spreadable cocoa and hazelnut cream (200 kcal), version 2+ 250 ml water

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cream version 3
Description: commercial spreadable cocoa and hazelnut cream (200 kcal), version 3+ 250 ml water

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: control chocolate bar
Description: commercial chocolate bar (200 kcal)+ 250 ml water
Study: NCT00699582

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2007 (perampanel)
Description: 8 mg perampanel in a 1:1:1 ratio, 125 subjects/arm. All subjects will take a maximum of 6 tablets daily for the duration of the study and will be up-titrated weekly in 2-mg increments to their randomized dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2007 (perampanel)
Description: 12 mg perampanel in a 1:1:1 ratio, 125 subjects/arm. All subjects will take a maximum of 6 tablets daily for the duration of the study and will be up-titrated weekly in 2-mg increments to their randomized dose.
Study: NCT03972878

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: chocolate bar version 1
Description: commercial chocolate bar (200 kcal), version 1+ 250 ml water
Study: NCT00699582

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo in a 1:1:1 ratio, 125 subjects/arm. All subjects will take a maximum of 6 tablets daily for the duration of the study.
Study: NCT00561964

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irbesartan
Description: Irbesartan capsules strength 150 mg. Irbesartan group will be initiated at one irbesartan and one placebo for 2 weeks and titrated at two capsules if well tolerated after 2 weeks , this dose will be maintained throughout the study without further dose-adjustment (2 capsules daily in the morning will be taken from randomization to study end)
Study: NCT02429791

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DTG 50 mg
Description: Participants received one oral tablet of 50 mg DTG daily administered concomitantly with RPV. Each DTG tablet contained 52.62 mg dolutegravir sodium salt, which was equivalent to 50 mg dolutegravir free acid.
Study: NCT00199290

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trafermin (genetical recombination)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trafermin (genetical recombination)
Study: NCT02429791

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RPV 25 mg
Description: Participants received one oral tablet of 25 mg RPV daily administered concomitantly with DTG along with a meal. Each RPV tablet contained 27.5 mg of rilpivirine hydrochloride, which was equivalent to 25 mg of RPV.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CAR
Description: CAR included the following combinations: 2 NRTIs + 1 INI, 2 NRTIs + 1 NNRTI, or 2 NRTIs + 1 PI
Study: NCT00199290

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Trafermin (genetical recombination)
Study: NCT05210686

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: subgingival re-instrumentation
Description: subgingival re-instrumentation (control)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: subgingival re-instrumentation
Description: subgingival re-instrumentation (control)
Study: NCT01385475

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RT
Description: 8 week RT Intervention
Study: NCT01577667

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intellivent; automatic mode implemented on a S1 ventilator
Description: Intellivent allows an automatic adjustment of the following parameters: FiO2, PEEP and %VM according to adjusted parameters: Size, SpO2 and EtCO2
Study: NCT00903617

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK256073
Description: 5 mg for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK256073
Description: 50 mg for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK256073
Description: 150 mg for 8 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo for 8 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo for 8 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Niaspan
Description: 1500 mg for 8 weeks
Study: NCT00561964

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo group: 2 placebo capsules daily as a single morning intake
Study: NCT03185637

Intervention type: PROCEDURE
Intervention: Various interventions for each of the conditions.
Description: This is an observational study. Patients were not allocated to different interventions.~Common interventions for each of the conditions, which will be compared during analysis include the following:~Gastroschisis - primary operative closure, surgical silo, preformed silo. Anorectal malformation - various types of stoma, anoplasty, PSARP, other. Appendicitis - antibiotics, open appendicectomy, laparoscopic appendicectomy. Intussusception - air enema reduction, hydro-enema reduction, laparotomy. Inguinal hernia - open repair, laparoscopic repair.

Intervention type: PROCEDURE
Intervention: Various interventions for each of the conditions.
Description: This is an observational study. Patients were not allocated to different interventions.~Common interventions for each of the conditions, which will be compared during analysis include the following:~Gastroschisis - primary operative closure, surgical silo, preformed silo. Anorectal malformation - various types of stoma, anoplasty, PSARP, other. Appendicitis - antibiotics, open appendicectomy, laparoscopic appendicectomy. Intussusception - air enema reduction, hydro-enema reduction, laparotomy. Inguinal hernia - open repair, laparoscopic repair.
Study: NCT00903617

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK256073
Description: x mg for 8 weeks based from data from Part A

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK256073
Description: optional dose based on data from Part A
Study: NCT04425746

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afamelanotide
Study: NCT02893618

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diazoxide choline controlled-release tablet
Description: QD tablet formulation of choline salt of diazoxide
Study: NCT04425746

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00089570

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: terlipressin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01940926

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-BNOTA-PRGD2
Description: Single dose intravenous injection of nearly 111 MBq 68Ga-BNOTA-PRGD2 at 30 minutes before PET/CT scanning
Study: NCT03185637

Intervention type: PROCEDURE
Intervention: Various interventions for each of the conditions.
Description: This is an observational study. Patients were not allocated to different interventions.~Common interventions for each of the conditions, which will be compared during analysis include the following:~Gastroschisis - primary operative closure, surgical silo, preformed silo. Anorectal malformation - various types of stoma, anoplasty, PSARP, other. Appendicitis - antibiotics, open appendicectomy, laparoscopic appendicectomy. Intussusception - air enema reduction, hydro-enema reduction, laparotomy. Inguinal hernia - open repair, laparoscopic repair.

Intervention type: PROCEDURE
Intervention: Various interventions for each of the conditions.
Description: This is an observational study. Patients were not allocated to different interventions.~Common interventions for each of the conditions, which will be compared during analysis include the following:~Gastroschisis - primary operative closure, surgical silo, preformed silo. Anorectal malformation - various types of stoma, anoplasty, PSARP, other. Appendicitis - antibiotics, open appendicectomy, laparoscopic appendicectomy. Intussusception - air enema reduction, hydro-enema reduction, laparotomy. Inguinal hernia - open repair, laparoscopic repair.

Intervention type: PROCEDURE
Intervention: Various interventions for each of the conditions.
Description: This is an observational study. Patients were not allocated to different interventions.~Common interventions for each of the conditions, which will be compared during analysis include the following:~Gastroschisis - primary operative closure, surgical silo, preformed silo. Anorectal malformation - various types of stoma, anoplasty, PSARP, other. Appendicitis - antibiotics, open appendicectomy, laparoscopic appendicectomy. Intussusception - air enema reduction, hydro-enema reduction, laparotomy. Inguinal hernia - open repair, laparoscopic repair.
Study: NCT00635804

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-3281
Description: MK-3281 capsule administered orally BID for 7 or 10 consecutive days depending on randomized dose. The PM dose of MK-3281 was not administered on Day 7 (for HCV-infected males) or Day 10 (for healthy males)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-3281
Description: MK-3281 capsule administered orally BID for 7 or 10 consecutive days depending on randomized dose. The PM dose of MK-3281 was not administered on Day 7 (for HCV-infected males) or Day 10 (for healthy males)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-3281
Description: MK-3281 capsule administered orally BID for 7 or 10 consecutive days depending on randomized dose. The PM dose of MK-3281 was not administered on Day 7 (for HCV-infected males) or Day 10 (for healthy males)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-3281
Description: MK-3281 capsule administered orally BID for 7 or 10 consecutive days depending on randomized dose. The PM dose of MK-3281 was not administered on Day 7 (for HCV-infected males) or Day 10 (for healthy males)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-3281
Description: MK-3281 capsule administered orally BID for 7 or 10 consecutive days depending on randomized dose. The PM dose of MK-3281 was not administered on Day 7 (for HCV-infected males) or Day 10 (for healthy males)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-3281
Description: MK-3281 capsule administered orally BID for 7 or 10 consecutive days depending on randomized dose. The PM dose of MK-3281 was not administered on Day 7 (for HCV-infected males) or Day 10 (for healthy males)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-3281
Description: MK-3281 capsule administered orally BID for 7 or 10 consecutive days depending on randomized dose. The PM dose of MK-3281 was not administered on Day 7 (for HCV-infected males) or Day 10 (for healthy males)
Study: NCT00885599

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Herbal API
Description: mouthwash;rinse full strength for 30 seconds with 20 ml (2/3 fl. Ounce or 4 teaspoonfuls) morning and night.
Study: NCT00504751

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mesna, cisplatin, etoposide, rituximab
Description: VIPER chemotherapy will be administered every 28 days at the following doses:~* Dexamethasone 40 mg IV days 1-4~* Ifosfamide 1.0 gram/m2 CIVI over 24 hours days 1-4~* Mesna 1.0 gram/m2 CIVI over 24 hours days 1-4 (mix solution with ifosfamide)~* Cisplatin 25 mg IV days 1-4~* Etoposide 100 mg/m2 CIVI over 24 hours days 1-4~* Rituximab 500 mg/m2 IV day 1 prior to start of DICE (375 mg/m2 for subsequent cycles)~* VELCADE 1.5 mg/m2 on days 2 and 5
Study: NCT02291575

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training
Description: (please see Arm Description)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: This group will not receive any training from the Liver Foundation; they will simply be evaluated at baseline and endline.
Study: NCT03506256

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norfloxacin 400 MG
Description: Norfloxacin is an oral fluoroquinolone antimicrobial agent used for the treatment of uncomplicated and complicated urinary tract infections. The drug antagonizes DNA gyrase, an enzyme essential for bacterial DNA replication and is active in vitro against virtually all bacterial pathogens causing urinary tract8
Study: NCT02856802

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sumatriptan 10 mg Nasal Spray
Description: 100 μL nasal spray once

Intervention type: OTHER
Group type: OTHER
Intervention: Sumatriptan Placebo Nasal Spray
Description: 100 μL nasal spray once
Study: NCT04365803

Intervention type: PROCEDURE
Intervention: vacuum-assisted breast biopsy
Description: patient with radiological complete response after neoadjuvant chemotherapy undergo to vacuum assisted breast biopsy and the to definitive surgery
Study: NCT03768362

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Plication strabismus surgery
Description: The technique was the same as resection up to muscle suturing, in the next step, the sutures were passed through 2 scleral bites at 1 mm anterior to the muscle insertion, then the muscle was folded toward inside or outside by pulling and joining the sutures. At the end, conjunctiva was repaired by vicryl 8/0.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Resection strabismus surgery
Description: resection strabismus surgery
Study: NCT00051935

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alglucosidase alfa
Description: 20 mg/kg (qow); intravenous
Study: NCT00635804

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to MK-3281
Description: Dose-matched placebo to MK-3281 capsule administered orally BID for 7 or 10 consecutive days depending on randomized dose of MK-3281 in serial panel. The PM dose of matched placebo was not administered on Day 7 or 10 (depending upon allocation).
Study: NCT04046029

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bivalirudin
Description: Bivalirudin will be given as a bolus of 0.75 mg/kg followed by infusion of 1.75 mg/kg/h during the PCI procedure and for at least 30 minutes but no more than 4 hours afterwards. Following this mandatory infusion,a reduced-dose infusion (0.2 mg/kg/h) for up to 20 hours could be administered at physician discretion. An additional bivalirudin bolus of 0.3 mg/kg was given if the activated clotting time 5 minutes after the initial bolus was less than 225 seconds.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Heparin
Description: Heparin will be administered at a dose of 70 to 100 units per kilogram in patients not receiving glycoprotein IIb/IIIa inhibitors and at a dose of 50 to 70 units per kilogram in patients receiving glycoprotein IIb/IIIa inhibitors. Subsequent adjustment of the heparin dose on the basis of the activated clotting time will be left to the discretion of the treating physicians.
Study: NCT00660829

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.15% Azelastine Hydrochloride
Description: 0.15% Azelastine Hydrochloride 822 mcg
Study: NCT02218424

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Study: NCT03395613

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NPWT
Description: Negative pressure wound thearpy on closed surgical wounds
Study: NCT01783795

Intervention type: OTHER
Group type: OTHER
Intervention: Genetic Analysis
Study: NCT00885599

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cepacol
Description: mouthwash;rinse full strength for 30 seconds with 20 ml (2/3 fl. Ounce or 4 teaspoonfuls) morning and night.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Listerine Antiseptic Mouth Rinse
Description: mouthwash;rinse full strength for 30 seconds with 20 ml (2/3 fl. Ounce or 4 teaspoonfuls) morning and night.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo mouthwash
Description: colored water mouthwash;rinse full strength for 30 seconds with 20 ml (2/3 fl. Ounce or 4 teaspoonfuls) morning and night.
Study: NCT03759340

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATI 502 0.46% Topical Solution
Description: apply ATI-502 Topical Solution, 0.46% Twice a day (BID) to the entire scalp and if applicable, the eyebrow(s)